Evidence map›Paper›PMID 24916648›Full record

ArticleEuropean journal of human genetics : EJHG2015

A genome-wide association study identifies PLCL2 and AP3D1-DOT1L-SF3A2 as new susceptibility loci for myocardial infarction in Japanese.

Megumi Hirokawa, Hiroyuki Morita, Tomoyuki Tajima, Atsushi Takahashi, Kyota Ashikawa, Fuyuki Miya, Daichi Shigemizu, Kouichi Ozaki, Yasuhiko Sakata, Daisaku Nakatani and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Scavenger receptor-targeted plaque delivery of microRNA-coated nanoparticles for alleviating atherosclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Fine-Mapping of theFrontiers in neurology · 2021
    Article
  16. Article
  17. Association of rs4618210A>G variant inJournal of cardiovascular and thoracic research · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 2 countries.

Megumi Hirokawa1] Laboratory for Genotyping Development, Center for Genomic Medicine, RIKEN Yokohama Institute, Yokohama, Japan [2] Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroyuki MoritaDepartment of Translational Research for Healthcare and Clinical Science, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tomoyuki Tajima1] Laboratory for Genotyping Development, Center for Genomic Medicine, RIKEN Yokohama Institute, Yokohama, Japan [2] Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Atsushi TakahashiLaboratory for Statistical Analysis, Center for Genomic Medicine, RIKEN Yokohama Institute, Yokohama, Japan.
Kyota AshikawaLaboratory for Genotyping Development, Center for Genomic Medicine, RIKEN Yokohama Institute, Yokohama, Japan.
Fuyuki MiyaLaboratory for Medical Informatics, Center for Genomic Medicine, RIKEN Yokohama Institute, Yokohama, Japan.
Daichi ShigemizuLaboratory for Medical Informatics, Center for Genomic Medicine, RIKEN Yokohama Institute, Yokohama, Japan.
Kouichi OzakiLaboratory for Cardiovascular Diseases, Center for Genomic Medicine, RIKEN Yokohama Institute, Yokohama, Japan.
Yasuhiko Sakata1] Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan [2] Department of Advanced Cardiovascular Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan [3] Department of Evidence-based Cardiovascular Medicine and Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Daisaku NakataniDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Shinichiro SunaDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Yasushi ImaiDepartment of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Toshihiro TanakaLaboratory for Cardiovascular Diseases, Center for Genomic Medicine, RIKEN Yokohama Institute, Yokohama, Japan.ORCID 0000000162019784
Tatsuhiko TsunodaLaboratory for Medical Informatics, Center for Genomic Medicine, RIKEN Yokohama Institute, Yokohama, Japan.
Koichi MatsudaLaboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000000172922686
Takashi KadowakiDepartment of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yusuke NakamuraLaboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Ryozo NagaiDepartment of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Issei Komuro1] Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan [2] Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Michiaki KuboLaboratory for Genotyping Development, Center for Genomic Medicine, RIKEN Yokohama Institute, Yokohama, Japan.
RIKEN Center for Integrative Medical Sciences · JPThe University of Tokyo · JPThe University of Osaka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite considerable progress in preventive and therapeutic strategies, myocardial infarction (MI) is one of the leading causes of death throughout the world. A total of 55 susceptibility genes have been identified mostly in European genome-wide association studies (GWAS). Nevertheless, large-scale GWAS from other population could possibly find additional susceptibility loci. To identify as many MI susceptibility loci as possible, we performed a large-scale genomic analysis in Japanese population. To identify MI susceptibility loci in Japanese, we conducted a GWAS using 1666 cases and 3198 controls using the Illumina Human610-Quad BeadChip and HumanHap550v3 Genotyping BeadChip. We performed replication studies using a total of 11,412 cases and 28,397 controls in the Japanese population. Our study identified two novel susceptibility loci for MI: PLCL2 on chromosome 3p24.3 (rs4618210:A>G, P = 2.60 × 10(-9), odds ratio (OR) = 0.91) and AP3D1-DOT1L-SF3A2 on chromosome 19p13.3 (rs3803915:A>C, P = 3.84 × 10(-9), OR = 0.89). Besides, a total of 14 previously reported MI susceptibility loci were replicated in our study. In particular, we validated a strong association on chromosome 12q24 (rs3782886:A>G: P = 1.14 × 10(-14), OR = 1.46). Following pathway analysis using 265 genes related to MI or coronary artery disease, we found that these loci might be involved in the pathogenesis of MI via the promotion of atherosclerosis. In the present large-scale genomic analysis, we identified PLCL2 and AP3D1-DOT1L-SF3A2 as new susceptibility loci for MI in the Japanese population. Our findings will add novel findings for MI susceptibility loci.

Indexed as

Genetic Predisposition to DiseaseGenome-Wide Association StudyAdaptor Protein Complex 3Adaptor Protein Complex delta SubunitsAdultAgedAllelesAsian PeopleCase-Control StudiesChromosomes, Human, Pair 12FemaleGene Regulatory NetworksGenotypeHistone-Lysine N-MethyltransferaseHumansIntracellular Signaling Peptides and ProteinsAdaptor Protein Complex 3Adaptor Protein Complex delta SubunitsAP3D1 protein, humanDOT1L protein, humanHistone-Lysine N-MethyltransferaseIntracellular Signaling Peptides and ProteinsMethyltransferasesPLCL2 protein, humanRNA-Binding ProteinsRNA Splicing FactorsSF3A2 protein, human

Identifiers

PMID24916648
PMCPMC4326706
OpenAlexW2087801463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.